Check Claims Before You Publish

Multidisciplinary portfolio: HIV in vivo models, long-acting antiretroviral (LA-ART) formulation work, CRISPR-based HIV interventions, and several plant/genomics collaborations. Evidence of first/lead authorship on technically complex in vivo therapeutic studies published in high-impact journals.

Objective evidence and interpretation

• High-impact translational HIV work: Dash is first author on a high-profile 2019 Nature Communications study combining long-acting ART and CRISPR in humanized mice, demonstrating partial viral elimination and detailed molecular work — this indicates technical competence in animal models, drug formulation collaborations, gene-editing delivery (AAV), sequencing and resistance interpretation. Nature Communications 2019 (CRISPR+LA-ART)
• Recent rigorous rebound/resistance analysis: A 2025 Communications Biology study including Dash reports deep-sequencing of rebound viruses following LA-ART ± CRISPR in humanized NSG mice, concluding rebound is driven primarily by ART-associated resistance and env diversification rather than CRISPR escape mutations — this shows deployment of NGS pipelines, drug-resistance databases (Stanford HIVdb), and population-level sequence interpretation. Communications Biology 2025 (Rebound signatures)
• Diverse collaborations: Dash’s author list includes both neuroscience/virology groups (humanized mice, neuroimaging, neuropathology) and plant/genomics groups (flax genome, aquaporin family work), indicating breadth across experimental systems and co-authorship networks that increase collaborative reach (e.g., Journal of Neuroscience 2011, Scientific Reports 2017). Journal of Neuroscience 2011 (Neurovirology)

Strengths (evidence-backed)

• Demonstrated ability to run and publish complex in vivo experiments combining pharmacology, gene editing, and NGS (Nature Comm 2019; Communications Biology 2025). Nature Communications 2019 (CRISPR+LA-ART)
• Frequent use of rigorous, field-standard analytic tools: Illumina MiSeq NGS, Stanford HIVdb, IAS-USA resistance lists, MAFFT/MUSCLE alignment — indicates familiarity with community-accepted bioinformatic/resistance pipelines (Communications Biology 2025 methods). Communications Biology 2025 methods

Limitations, blindspots and critical caveats

• Authorship / metric ambiguity: Multiple individuals named "Prasanta K. Dash" (and similar variants) exist in bibliographic databases — OpenAlex shows one high-impact profile (h-index ~33, works_count 139) and several low-coverage entries (h-index 1–6). Careful disambiguation is required before assigning aggregate metrics to a single person; institutional affiliations are sometimes missing, increasing identification risk. (Data excerpt: OpenAlex multiple matches.)
• Reproducibility / sample sizes: The Communications Biology 2025 rebound study used modest animal numbers per group (total n=29 samples across two strains), and authors note split cohorts and strain-specific differences; these limit generalizability and statistical power for some subgroup claims. The publication itself lists these as limitations. Communications Biology 2025 limitations
• Potential conflicts in translation: The 2025 paper lists an author COI (Howard E. Gendelman co-founding Exavir Therapeutics), and several LA-ART technologies have translational/commercial interest — users should weigh financial-incentive bias in interpretation of translational claims. COI and funding disclosure (2025)
• Tissue reservoirs vs plasma: The rebound study used plasma-derived sequences; authors acknowledge that reservoir tissues may harbor different escape dynamics and that plasma alone can under-represent proviral/latent reservoirs — this is a key caveat for inferring total viral elimination. Plasma vs tissue reservoir limitation

Concrete, evidence-based recommendations for improving scientific strength

1. Disambiguate bibliometrics: ensure publications and metrics (h-index, citations) map to the correct ORCID/OpenAlex identity and list institutional affiliations to remove ambiguity.
2. Increase cohort and tissue-sampling depth in future in vivo studies (greater n, systematic tissue reservoir sampling, functional resistance assays) to strengthen causal inferences about elimination vs rebound.
3. Provide CRISPR off-target analyses and in-depth phylogenetic clustering of rebound sequences (beyond plasma highlighter plots) to directly test CRISPR-driven escape hypotheses; include functional validation of novel mutations where feasible.
4. Make raw NGS reads and pipeline code available in public repositories (SRA/ENA + GitHub) to maximize reproducibility and independent reanalysis.

Representative key papers (evidence links)

• Nature Communications (2019) — first-authored study combining LA-ART and CRISPR in humanized mice (technical centerpiece). Nature Communications 2019
• Communications Biology (2025) — rebound viruses and resistance signatures after LA-ART ± CRISPR: careful NGS/resistance mapping. Communications Biology 2025
• Journal of Neuroscience (2011) — neurodegeneration in HIV-infected humanized mice (demonstrates breadth into neurovirology). Journal of Neuroscience 2011

What would change my appraisal (falsification tests)

• Clear CRISPR off-target/escape signatures in proviral tissue reservoirs demonstrating CRISPR-driven selection would shift credit from ART resistance to CRISPR-escape and change interpretation of dual-therapy failure.
• Independent replication with larger cohorts and systematic tissue sampling showing near-complete elimination would substantially raise confidence in translational claims.

Quick practical next actions

1. Map author name variants to a single ORCID and publish a consolidated bibliography to clarify metrics.
2. Deposit raw NGS reads and analysis scripts in public repositories with DOIs to increase reusability and reproducibility.